| 08:06a | GLAXOSMITHKLINE : UBS remains Neutral | MD |
| 08:04a | GLAXOSMITHKLINE : Credit Suisse remains a Sell rating | MD |
| 07:49a | VectivBio Gets Orphan Drug Designation for Apraglutide | DJ |
| 07:44a | Gilead Sciences Sees Positive Results From Trial for Hepatitis Treatment | DJ |
| 07:36a | Prothena to Get $80 Million After Bristol Myers Exercises Option for Alzheimer's Treatment | DJ |
| 07:14a | Eli Lilly Gets Breakthrough Therapy Designation for Alzheimer's Treatment From FDA | DJ |
| 07:13a | BAYER AG : UBS reaffirms its Buy rating | MD |
| 06:50a | Pieris Pharmaceuticals Gets Orphan Drug Designation for Gastric Cancer Treatment | DJ |
| 06:37a | Roche Eye-Treatment Application Accepted | DJ |
| 06:35a | NOVO NORDISK : JP Morgan maintains a Buy rating | MD |
| 06:35a | NOVO NORDISK : Gets a Buy rating from Deutsche Bank | MD |
| 06:32a | GLAXOSMITHKLINE : Deutsche Bank Upgrades to Neutral | MD |
| 03:29a | GLAXOSMITHKLINE : Barclays reiterates its Sell rating | MD |
| 03:17a | GLAXOSMITHKLINE : Gets a Buy rating from Jefferies | MD |
| 02:45a | SIEMENS HEALTHINEERS : raises growth target and launches share buyback | RE |
| 02:02a | DGAP-PVR : Bayer Aktiengesellschaft: Release -2- | DJ |
| 01:00a | PRESS RELEASE : FDA accepts application for -2- | DJ |
| 01:00a | PRESS RELEASE : FDA accepts application for Roche's Port Delivery System with ranibizumab (PDS) for treatment of neovascular or "wet" age-related macular degeneration (nAMD) | DJ |
| 01:00a | PRESS RELEASE : Santhera and ReveraGen to Present -2- | DJ |
| 01:00a | PRESS RELEASE : Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference | DJ |
| 01:00a | PRESS RELEASE : ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting | DJ |
| 01:00a | Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference | DJ |
| 12:31a | China stocks slip as healthcare firms retreat; Hong Kong up | RE |
| 12:23a | AstraZeneca's Lynparza Drug Approved in China for Prostate Cancer | DJ |
| 06/23 | MODERNA : U.S. administers 319.9 mln doses of COVID-19 vaccines - CDC | RE |
| 06/23 | EISAI : drug for Alzheimer's with Biogen gets breakthrough status in U.S. | RE |
| 06/23 | BIOGEN : drug for Alzheimer's with Eisai gets breakthrough status in U.S | RE |
| 06/23 | MODERNA : U.S. CDC Says Administered 319,872,053 Doses Of Covid-19 Vaccine As Of June 23 | RE |
| 06/23 | MODERNA : NIH begins clinical trial testing COVID-19 vaccine in pregnant women | RE |
| 06/23 | BIOGEN : working to speed up confirmatory study for approved Alzheimer's drug | RE |
| 06/23 | GILEAD SCIENCES : Unauthorized COVID-19 drugs bound for Mexico seized by U.S. authorities - WSJ | RE |
| 06/23 | FTSE 100 Closed Down Despite Outperforming European Indexes | DJ |
| 06/23 | MODERNA : 'Likely link' between rare heart inflammation and Pfizer, Moderna vaccines -CDC advisers | RE |
| 06/23 | GLAXOSMITHKLINE : Goldman Sachs remains its Buy rating | MD |
| 06/23 | GLAXOSMITHKLINE : JP Morgan sticks Neutral | MD |
| 06/23 | FACTBOX : How GSK plans to fire-up its cash balance post split | RE |
| 06/23 | FORM 8.3 - THE VANGUARD GROUP, INC. : Spire Healthcare Group plc | DJ |
| 06/23 | FORM 8.3 - THE VANGUARD GROUP, INC. : Xeris Pharmaceuticals, Inc | DJ |
| 06/23 | FORM 8.3 - THE VANGUARD GROUP, INC. : UDG Healthcare plc | DJ |
| 06/23 | FORM 8.3 - THE VANGUARD GROUP, INC. : Strongbridge Biopharma plc | DJ |
| 06/23 | ORIGINAL-RESEARCH : Cardiol Therapeutics (von GBC AG): BUY | DJ |
| 06/23 | Genprex Shares Rise 8% on FDA Review of Reqorsa Trial | DJ |
| 06/23 | GLAXOSMITHKLINE : Reaction to GSK's plan to spin off its consumer healthcare business | RE |
| 06/23 | PRESS RELEASE : Dermapharm Holding SE: Annual General Meeting approves dividend distribution of EUR 0.88 per share | DJ |
| 06/23 | PRESS RELEASE : CureVac Provides Supervisory Board Update | DJ |
| 06/23 | Pfizer Says First Patient Dosed in Phase 3 Prostate-Cancer Trial | DJ |
| 06/23 | CVRx Sets IPO at 6.25 Million Shares; Sees Pricing at $15-$17 Each | DJ |
| 06/23 | DGAP-PVR : Gerresheimer AG: Release according to -2- | DJ |
| 06/23 | DGAP-PVR : Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | DJ |
| 06/23 | GlaxoSmithKline Expects Long-Term Sales, Profit Growth, Driven by Vaccines and Specialty Medicines -- Update | DJ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
